By Medeea GreereFebruary 9, 2025Updated:February 9, 20251 Comment5 Mins Read
TwitterFacebookTelegramWhatsAppEmail
![New Breakthrough: Dr. William Makis MD Explores Methylene Blue as a Powerful Therapy for Androgen-Dependent and Androgen-Independent Prostate Cancer New Breakthrough: Dr. William Makis MD Explores Methylene Blue as a Powerful Therapy for Androgen-Dependent and Androgen-Independent Prostate Cancer](https://amg-news.com/wp-content/uploads/2025/02/Methylene-Blue-as-a-Powerful-Therapy-for-Androgen-Dependent-and-Androgen-Independent-Prostate-Cancer.jpeg)
Share
New Breakthrough: Dr. William Makis MD Explores Methylene Blue as a Powerful Therapy for Androgen-Dependent and Androgen-Independent Prostate Cancer
Ready to uncover the truth? Sick of the lies? Join our Telegram Channel now. It’s time for the real story! My gratitude to all my readers!
Discover the promising potential of Methylene Blue (MB) in prostate cancer treatment, as highlighted in groundbreaking research from the AACR Annual Meeting 2019. Learn how MB effectively targets androgen-dependent and androgen-independent prostate cancer cells, induces apoptosis, inhibits tumor growth and metastasis, and could become a game-changer in oncology.
Insights from Dr. William Makis MD, a leading oncologist, radiologist, and cancer researcher with 100+ publications. Read more about this emerging anticancer therapy and stay tuned for upcoming dosage recommendations!
https://platform.twitter.com/embed/Tweet.html?creatorScreenName=GreereMedeea&dnt=false&embedId=twitter-widget-0&features=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%3D%3D&frame=false&hideCard=false&hideThread=false&id=1888551484192616737&lang=en&maxWidth=560px&origin=https%3A%2F%2Famg-news.com%2Fnew-breakthrough-dr-william-makis-md-explores-methylene-blue-as-a-powerful-therapy-for-androgen-dependent-and-androgen-independent-prostate-cancer%2F&sessionId=5afd212a7d667911381a2868ada08304d5094a26&siteScreenName=GreereMedeea&theme=light&widgetsVersion=2615f7e52b7e0%3A1702314776716&width=550px
Methylene Blue: A Promising Therapeutic Agent in Prostate Cancer Treatment
Prostate cancer remains one of the most prevalent malignancies among men worldwide, with treatment options evolving as research uncovers new therapeutic possibilities. One such promising agent is Methylene Blue (MB), a compound with a well-documented history in medicine and emerging evidence supporting its anticancer properties.
A notable study presented at the 2019 AACR Annual Meeting (American Association for Cancer Research) by Shanti et al. explored the potential of MB in targeting both androgen-dependent and androgen-independent prostate cancer cells. The findings of this study highlight Methylene Blue’s multifaceted role in inhibiting tumor growth and promoting apoptosis in cancer cells, positioning it as a potential breakthrough in prostate cancer treatment.
Don’t Miss This:
Key Findings of the Study
The research by Shanti et al. investigated the effects of MB on three prostate cancer cell lines:
- LNCaP (androgen-dependent)
- PC3 and DU145 (androgen-independent)
![](https://amg-news.com/wp-content/uploads/2025/02/GjVora_XYAElsVo.jpeg)
![](https://amg-news.com/wp-content/uploads/2025/01/PROVIVE.png)
1. Reduction of Cancer Cell Viability
Methylene Blue effectively decreased the viability of both androgen-dependent and androgen-independent prostate cancer cells, demonstrating its broad-spectrum potential.
2. Inhibition of Tumor Colony Formation
The study revealed that MB suppressed the ability of prostate cancer cells to form colonies in vitro, suggesting its potent tumor-suppressive capabilities.
3. Disruption of Cancer Cell Migration
A wound healing assay indicated that MB significantly impaired the migration potential of prostate cancer cells, underlining its role as an anti-metastatic agent.
4. Induction of Apoptotic Cell Death
MB induced apoptosis, or programmed cell death, in prostate cancer cells, a crucial mechanism in effective cancer therapy. Notably, key apoptotic markers were robustly upregulated in LNCaP cells following MB treatment:
- Bax
- TRAIL R2/D5
- Phospho p53 (Serine 15, Serine 46, Serine 392)
These findings suggest that Methylene Blue’s mechanism of action involves the activation of apoptotic pathways, leading to significant cancer cell death.
![](https://amg-news.com/wp-content/uploads/2025/02/Home-Doctor.png)
The Future of Methylene Blue in Cancer Treatment
Although this study was presented as an abstract, its findings underscore MB’s potential as a powerful anticancer agent. The exact mechanisms of Methylene Blue’s action on cancer cells are still being explored, but emerging evidence suggests multiple pathways are involved, much like we have seen with repurposed drugs such as Ivermectin and Fenbendazole.
As research continues, it is becoming increasingly evident that MB holds promise not just in prostate cancer treatment but possibly in other malignancies as well. With its known safety profile and broad-spectrum biological effects, Methylene Blue could be a game-changer in oncological therapies.
ALSO: MAKE AMERICA HEALTHY AGAIN: HOME RETREAT | HOW TO RENEW YOUR CELLS IN 7 DAYS
Conclusion. The study presented at the 2019 AACR Annual Meeting is a significant step toward understanding Methylene Blue’s potential in prostate cancer therapy. By targeting both hormone-dependent and hormone-independent prostate cancer cells, MB demonstrates versatility as an anticancer agent.
Dr. William Makis, MD, a highly esteemed radiologist, oncologist, and cancer researcher with over 100+ publications, is dedicated to uncovering new cancer treatment avenues. His contributions to cancer research continue to push the boundaries of modern medicine, offering hope for innovative and effective therapeutic strategies.
Stay tuned for more insights into Methylene Blue’s role in cancer therapy and an upcoming proposed MB dosing plan in the following week!
Video Player
00:00
답글 남기기
댓글을 달기 위해서는 로그인해야합니다.